Form 8.3 - Allergan plc – Company Announcement

Allergan plc

Form 8.3 - Allergan plc

Dec 10 2019 15:00 GMTSource: RNS

RNS Number : 3560W

Citadel Group

10 December 2019

Ap 19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

Name of person dealing (Note 1)

Citadel Group

Company dealt in

ALLERGAN PLC

Class of relevant security to which the dealings being disclosed relate (Note 2)

Common Stock ISIN IE00BY9D5467

Date of dealing

09 December, 2019

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security

dealt in (Note 3)

	Long	Short
Common Stock ISIN IE00BY9D5467	Number (%)	Number (%)
(1) Relevant securities	1,566,345 (0.48%)	1,833 (0.00%)
(2) Derivatives (other than options)	3,892,036 (1.19%)	9,226 (0.00%)
(3) Options and agreements to purchase/sell	500,000 (0.15%)	610,200 (0.19%)
Total	5,958,381(1.82%)	621,259 (0.19%)

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

	Long	Short
	Number (%)	Number (%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap 20

1. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale Common Stock ISIN IE00BY9D5467	Number of securities	Price per unit (Note 5)
a buy	878	185.27 USD
a buy	626	185.955 USD
a sell	-878	185.27 USD
a sell	-626	185.955 USD
Purchase	751	185.27 USD
Purchase	100	185.39 USD
Purchase	100	185.41 USD
Purchase	100	185.42 USD
Purchase	200	185.45 USD
Purchase	223	185.46 USD
Purchase	105	185.47 USD
Purchase	215	185.49 USD
Purchase	100	185.495 USD
Purchase	500	185.5 USD
Purchase	400	185.55 USD
Purchase	100	185.56 USD
Purchase	348	185.57 USD
Purchase	597	185.8 USD
Purchase	180	185.87 USD
Purchase	200	185.9 USD
Purchase	100	185.92 USD
Purchase	100	185.96 USD
Purchase	100	185.97 USD
Purchase	161	185.98 USD
Purchase	109	185.99 USD
Purchase	568	186 USD
Purchase	555	186.01 USD
Purchase	209	186.02 USD
Purchase	514	186.03 USD
Purchase	201	186.04 USD
Purchase	300	186.05 USD
Purchase	105	186.06 USD
Purchase	360	186.08 USD
Purchase	104	186.09 USD
Purchase	304	186.1 USD
Purchase	184	186.11 USD
Purchase	546	186.12 USD
Purchase	617	186.13 USD
Purchase	849	186.14 USD
Purchase	50	186.15 USD
Purchase	659	186.15 USD
Purchase	1,305	186.16 USD
Purchase	100	186.17 USD
Purchase	318	186.18 USD
Purchase	46	186.19 USD
Purchase	312	186.2 USD
Purchase	304	186.21 USD
Purchase	100	186.215 USD
Purchase	910	186.22 USD
Purchase	619	186.23 USD
Purchase	883	186.24 USD
Purchase	170	186.25 USD
Purchase	691	186.26 USD
Purchase	200	186.265 USD
Purchase	8	186.27 USD
Purchase	123	186.28 USD
Purchase	300	186.31 USD
Purchase	205	186.33 USD
Purchase	117	186.37 USD
Purchase	529	186.38 USD
Purchase	75	186.3828 USD
Purchase	174	186.38569 USD
Purchase	100	186.39 USD
Purchase	699	186.4 USD
Purchase	499	186.41 USD
Purchase	299	186.42 USD
Purchase	13	186.435 USD
Purchase	711	186.44 USD
Purchase	141	186.45 USD
Purchase	200	186.47 USD
Purchase	34	186.48 USD
Purchase	100	186.5 USD
Purchase	800	186.51 USD
Purchase	100	186.52 USD
Purchase	400	186.53 USD
Purchase	300	186.54 USD
Purchase	300	186.55 USD
Purchase	200	186.56 USD
Purchase	101	186.57 USD
Purchase	100	186.58 USD
Purchase	4	186.59 USD
Purchase	200	186.65 USD
Purchase	100	186.665 USD
Purchase	114	186.685 USD
Purchase	184	186.69 USD
Purchase	5	186.7 USD
Purchase	44	186.74 USD
Purchase	100	186.76 USD
Purchase	200	186.77 USD
Purchase	188	186.8 USD
Sale	-2,103	185.27 USD
Sale	-127	185.27 USD
Sale	-100	185.45 USD
Sale	-290	185.46 USD
Sale	-300	185.47 USD
Sale	-210	185.49 USD
Sale	-608	185.5 USD
Sale	-100	185.54 USD
Sale	-300	185.59 USD
Sale	-40	185.63 USD
Sale	-303	185.67 USD
Sale	-200	185.74 USD
Sale	-285	185.82 USD
Sale	-503	185.87 USD
Sale	-109	185.91 USD
Sale	-314	185.95 USD
Sale	-13	185.965 USD
Sale	-202	185.97 USD
Sale	-1	185.99 USD
Sale	-200	186 USD
Sale	-30	186.01 USD
Sale	-99	186.04 USD
Sale	-300	186.05 USD
Sale	-100	186.07 USD
Sale	-111	186.09 USD
Sale	-100	186.11 USD
Sale	-305	186.12 USD
Sale	-776	186.13 USD
Sale	-400	186.14 USD
Sale	-200	186.145 USD
Sale	-629	186.15 USD
Sale	-31	186.155 USD
Sale	-423	186.16 USD
Sale	-300	186.17 USD
Sale	-204	186.18 USD
Sale	-301	186.19 USD
Sale	-1,285	186.2 USD
Sale	-753	186.21 USD
Sale	-100	186.22 USD
Sale	-1,056	186.23 USD
Sale	-20	186.235 USD
Sale	-111	186.24 USD
Sale	-639	186.25 USD
Sale	-182	186.26 USD
Sale	-10	186.27 USD
Sale	-188	186.28 USD
Sale	-100	186.285 USD
Sale	-105	186.29 USD
Sale	-40	186.3 USD
Sale	-599	186.31 USD
Sale	-300	186.32 USD
Sale	-250	186.33 USD
Sale	-100	186.35 USD
Sale	-30	186.36 USD
Sale	-171	186.37 USD
Sale	-418	186.38 USD
Sale	-661	186.39 USD
Sale	-20	186.41 USD
Sale	-100	186.42 USD
Sale	-454	186.43 USD
Sale	-200	186.44 USD
Sale	-112	186.45 USD
Sale	-201	186.5 USD
Sale	-6	186.51 USD
Sale	-100	186.54 USD
Sale	-399	186.55 USD
Sale	-100	186.59 USD
Sale	-565	186.6 USD
Sale	-100	186.64 USD
Sale	-100	186.68 USD
Sale	-100	186.69 USD
Sale	-200	186.82 USD
Sale	-100	186.83 USD

(b) Derivatives transactions (other than options transactions)

Product name,

e.g. CFD

ISIN

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

(i) Writing, selling, purchasing or varying

Product name, e.g. call option

Writing, selling, purchasing,

varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type,e.g. American, European etc.

Expiry date

Option money paid/ received per unit (Note 5)

(ii) Exercising

Product name,

e.g. call option

Number of securities

Exercise price per unit

(Note 5)

(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

Ap 21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated

None

Is a Supplemental Form 8 attached? (Note 9)

YES

Date of disclosure:	10 December, 2019
Contact name:	Katie Bonds
Telephone number:	020 7645 9700
If a connected EFM, name of offeree/offeror with which connected	n/a
If a connected EFM, state nature of connection (Note 10)	n/a

Ap23

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DETAILS OF OPEN POSITIONS

(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)

OPEN POSITIONS (Note 1)

Product name, e.g. call option	Written, or purchased	Number of relevant securities to which the option or derivative relates	Exercise price (Note 2)	Type, e.g. American, European etc.	Expiry date
Put Option	Written	500,000	145 USD	American	12/20/2019
Put Option	Purchased	-500,000	155 USD	American	12/20/2019
Put Option	Purchased	-110,200	180 USD	American	01/17/2020

Notes

1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.

2. For all prices and other monetary amounts, the currency must be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

ISEGMMMZGGDGLZM

Company Announcements

Form 8.3 - Allergan plc